ICONIC-LEAD achieved its co-primary endpoints of PASI-90 and IGA of 0 or 1 at week 16; 74% of patients achieved...
Marked and rapid reductions in both pericarditis pain and inflammation maintained throughout the 26-week studyEpisodes of pericarditis per year substantially...
SAN FRANCISCO, Nov. 18, 2024 /PRNewswire/ -- H.I.G. Growth Partners ("H.I.G. Growth"), the dedicated growth capital investment affiliate of H.I.G....
Two patients exceed 14 months on treatment in Phase 2 trial of advanced ovarian cancerAllarity maintains a cash balance of...
RTY-694 increased protein levels and function of ABCB4 and BSEP in primary hepatocytes, two transporters that play a key role in...
Topline results expected in early January 2025CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a...
NEWTOWN, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company...
BRISBANE, Calif., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a late clinical-stage biotechnology company focused on...
Subset analysis of FASCINATE-2 Phase 2 trial demonstrated denifanstat improved fibrosis in difficult-to-treat MASH patients Both artificial intelligence (AI) and...
– sdATEVs maintained sustained patency throughout the six-month study – – sdATEV was observed to recellularize with host cells and...
Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens...
Next generation product may increase gastrointestinal luminal concentration while limiting system exposure LAVAL, QC / ACCESSWIRE / November 18, 2024...
EnteroBiotix Completes Phase 2 Study Recruitment of EBX-102-02 in Irritable Bowel Syndrome 122 patients with moderate to severe irritable bowel...
LAVAL, QC / ACCESSWIRE / November 18, 2024 / Bausch Health, Canada Inc., part of Bausch Health Companies Inc. (NYSE/TSX:BHC),...
ZÜRICH, SWITZERLAND / ACCESSWIRE / November 18, 2024 / NLS Pharmaceutics Ltd. (Nasdaq:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage...
SAN DIEGO, Nov. 18, 2024 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing...
Icovamenib Achieves a Mean Reduction in HbA1c Greater than 1% at Week 26 Following 4 Weeks of Dosing in Type...
INX-315, a potential best-in-class CDK2 inhibitor, to be evaluated in combination with Verzenio® (abemaciclib) and fulvestrant Combination therapy to be...
Promotes Edward Brennan, MD, FACS to Chief Scientific Officer & Head of R&D ProgramTORONTO and PHILADELPHIA, Nov. 18, 2024 (GLOBE...
Phase 2 CLOVER-WaM pivotal study data selected for oral presentation at 66th Annual American Society of Hematology Meeting and Exposition...